← SynDRA
ETOPOSIDE PHOSPHATE
SynDRA canonical compound SYN0023106 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TOP2A |
|---|
| Mechanism of action | topoisomerase inhibitor |
|---|
| Indication | small cell lung cancer | testicular carcinoma |
|---|
| Disease area | oncology |
|---|
All known targets
- TOP2A
- TOP2B
- CYP2E1
- CYP3A5
- ABCB1
- ABCC2
- NR1I2
- ABCC1
- ABCG2
- ABCC6
- ABCC3
- ALOX15
Mechanisms of action (all sources)
- TOP2A INHIBITOR
- DNA topoisomerase II alpha inhibitor
- topoisomerase inhibitor
- DNA topoisomerase II inhibitor
- TOP2B INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Drug classes
- Topoisomerase Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Enzyme Inhibitors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitor
ATC classes
- L01C · PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Cross-references
Synonyms
- ETOPOPHOS PRESERVATIVE FREE
- etopofos
- etopophos
- Vepeside
- BMY-40481
- VP-16
- VP16
- Etopophos
- Etopophos preservative free
- etoposide.phosphate
- Etopofos
- Etopophos Preservative Free
- Etoposide 4'-Phosphate
- Etoposide phosphate [USAN]
- 528XYJ8L1N
- Etophos
- Etoposide phosphate (USAN)
- UNII-528XYJ8L1N
- Etopophos (TN)
- NCGC00185753-01
- Eposin Etopophos Vepesid VP16
- Etoposide Phosphate (Etopophos)
- CHEMBL1200645
- ETOPOSIDE PHOSPHATE [MI]
- SCHEMBL13318053
- CHEBI:135867
- ETOPOSIDE PHOSPHATE [VANDF]
- ETOPOSIDE PHOSPHATE [MART.]
- EX-A3595
- ZINC3920020
- BDBM50247889
- ETOPOSIDE PHOSPHATE [USP-RS]
- ETOPOSIDE PHOSPHATE [WHO-DD]
- MFCD00270859
- AKOS025311200
- ETOPOSIDE PHOSPHATE [ORANGE BOOK]
- NCGC00185753-04
- AS-12896
Reported adverse events
- Nausea
- Myelosuppression
- Abdominal pain
- Rash
- Stomatitis
- Hypersensitivity
- Alopecia
- Hypertension
- Leukopenia
- Thrombocytopenia
- Death
- Hypotension
Look up ETOPOSIDE PHOSPHATE in the interactive SynDRA portal →